Elevar Therapeutics, the U.S. subsidiary of HLB, said Monday that it has participated in Bio Europe Spring in Basel, Switzerland, from March 20-22.

Bio Europe Spring is the largest bio conference in Europe attended by global biopharmaceutical companies and investors. Global big pharma, such as Nova Novartis, Roche and Pfizer, participate in the conference every year to discuss cooperation.

Elevar discussed the commercialization of Rivoceranib, HLB’s targeted anticancer agent, in Europe. The company has set about to prepare for winning European approval for Rivoceranib as the primary treatment of liver cancer and consequent commercialization. Elevar has global marketing rights for Rivoceranib.

HLB and Elevar plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration in May for Rivoceranib as the primary treatment of liver cancer and will push ahead with application procedures in other major markets, including Europe and Asia. Notably, HLB is considering a strategy in which it directly sells Rivoceranib in the U.S. and transfers its technology to a partner in Europe.

“Since we released the results of the phase 3 clinical trial for Rivoceranib at the European Society for Medical Oncology (ESMO), we have received inquiries about its commercialization plan and separate investigator-led clinical trials from many specialists in the U.S. and Europe,” said Han Yong-hae, CEO of HLB Life Science who also serves as CTO of the HLB Group.

Han added that if it shows signs of winning a new drug approval beginning in the U.S., a broader clinical trial, including liver cancer and many other indications, would likely follow.